- Public Comps
- Inoviq
Inoviq Valuation Multiples
Discover Inoviq's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Rhythm Biosciences, CelLBxHealth, Genematrix, Urteste and more.
Inoviq Overview
About Inoviq
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
Founded
1983
HQ

Employees
85
Website
Financials (FY)
EV
$10M
Valuation Multiples
Start free trialInoviq Financials
Inoviq reported last fiscal year revenue of $387K and negative EBITDA of ($5M).
In the same fiscal year, Inoviq generated $302K in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).
Revenue (LTM)
Inoviq P&L
In the most recent fiscal year, Inoviq reported revenue of $387K and EBITDA of ($5M).
Inoviq is unprofitable as of last fiscal year, with gross margin of 78%, EBITDA margin of (1317%), and net margin of (1266%).
Financial data powered by Morningstar, Inc.
Inoviq Stock Performance
Inoviq has current market cap of $19M, and enterprise value of $10M.
Market Cap Evolution
Inoviq's stock price is $0.14.
Inoviq share price increased by 1.5% in the last 30 days, and decreased by 48.5% in the last year.
Inoviq has an EPS (earnings per share) of $-0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $19M | 2.6% | 1.5% | -40.8% | -48.5% | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInoviq Valuation Multiples
Inoviq trades at 25.4x EV/Revenue multiple, and (1.9x) EV/EBITDA.
EV / Revenue (LTM)
Inoviq Financial Valuation Multiples
As of August 15, 2026, Inoviq has market cap of $19M and EV of $10M.
Inoviq has a P/E ratio of (4.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Inoviq Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Inoviq Margins & Growth Rates
Inoviq grew revenue by 63% but EBITDA decreased by 17% in the last fiscal year.
In the most recent fiscal year, Inoviq reported gross margin of 78%, EBITDA margin of (1317%), and net margin of (1266%).
Inoviq Margins
Inoviq Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Inoviq Operational KPIs
Inoviq's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Inoviq's Rule of 40 is (386%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inoviq's Rule of X is (247%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Inoviq Competitors
Inoviq competitors include Rhythm Biosciences, CelLBxHealth, Genematrix, Urteste, Biovica International, Read-Gene, EZZ Life Science, BCAL Diagnostics, Microba Life Sciences and Bionano Genomics.
Most Inoviq public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1082.4x | - | (7.6x) | - | |||
| 10.2x | 7.6x | (1.0x) | (1.6x) | |||
| 1.6x | - | (14.5x) | - | |||
| 2888.7x | - | (11.7x) | - | |||
| 6.4x | 5.0x | (1.4x) | (1.4x) | |||
| 4.0x | - | 68.9x | - | |||
| 0.1x | - | 0.8x | - | |||
| 959.3x | - | (3.4x) | - | |||
This data is available for Pro users. Sign up to see all Inoviq competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Inoviq
Inoviq has acquired 1 company to date.
Last acquisition by Inoviq was on July 1st 2020. Inoviq acquired Sienna Cancer Diagnostics for $16M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Inoviq
| Description | Sienna Cancer Diagnostics is a Perth-based developer of in vitro diagnostic tests and reagents for cancer detection. The company commercializes biomarkers for prostate, bladder, and breast cancers through partnerships with global labs and hospitals. Sienna's portfolio includes Progensa PCA3 assay for prostate cancer risk assessment and collaborates with clinical networks in Australia, Europe, and Asia for validation and distribution. |
| HQ Country | |
| HQ City | Melbourne |
| Deal Date | 1 Jul 2020 |
| Valuation | $16M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Inoviq acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Inoviq
| When was Inoviq founded? | Inoviq was founded in 1983. |
| Where is Inoviq headquartered? | Inoviq is headquartered in Australia. |
| How many employees does Inoviq have? | As of today, Inoviq has over 85 employees. |
| Is Inoviq publicly listed? | Yes, Inoviq is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Inoviq? | Inoviq trades under IIQ ticker. |
| When did Inoviq go public? | Inoviq went public in 1991. |
| Who are competitors of Inoviq? | Inoviq main competitors include Rhythm Biosciences, CelLBxHealth, Genematrix, Urteste, Biovica International, Read-Gene, EZZ Life Science, BCAL Diagnostics, Microba Life Sciences, Bionano Genomics. |
| What is the current market cap of Inoviq? | Inoviq's current market cap is $19M. |
| What is the current revenue of Inoviq? | Inoviq's last fiscal year revenue is $387K. |
| What is the current revenue growth of Inoviq? | Inoviq revenue growth (vs. last FY) is 63%. |
| What is the current EV/Revenue multiple of Inoviq? | Current revenue multiple of Inoviq is 25.4x. |
| Is Inoviq profitable? | No, Inoviq is not profitable. |
| How many companies Inoviq has acquired to date? | As of August 2026, Inoviq has acquired 1 company. |
| What was the largest acquisition by Inoviq? | $16M acquisition of Sienna Cancer Diagnostics on 1st July 2020 was the largest M&A Inoviq has done to date. |
| What companies Inoviq acquired? | Inoviq acquired Sienna Cancer Diagnostics. |
| In how many companies Inoviq has invested to date? | Inoviq hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Inoviq
Lists including Inoviq
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





